K. O. Shnaider, M. Maksimov, B. Romanov, A. Shikaleva
{"title":"Omalizumab的不良反应和安全性","authors":"K. O. Shnaider, M. Maksimov, B. Romanov, A. Shikaleva","doi":"10.33920/med-03-2208-07","DOIUrl":null,"url":null,"abstract":"Omalizumab is one of the longest-used monoclonal antibodies and the first available treatment option for severe allergic asthma in patients aged 6 years and older. Its efficacy and safety were established in several randomized controlled trials, leading to its final registration over 15 years ago. In most cases, long-term treatment with omalizumab is safe and does not increase the risk of adverse reactions. However, over the years, there has been a trend towards an increase in the registration of adverse events associated with the use of omalizumab.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"87 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Omalizumab adverse reactions and safety\",\"authors\":\"K. O. Shnaider, M. Maksimov, B. Romanov, A. Shikaleva\",\"doi\":\"10.33920/med-03-2208-07\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Omalizumab is one of the longest-used monoclonal antibodies and the first available treatment option for severe allergic asthma in patients aged 6 years and older. Its efficacy and safety were established in several randomized controlled trials, leading to its final registration over 15 years ago. In most cases, long-term treatment with omalizumab is safe and does not increase the risk of adverse reactions. However, over the years, there has been a trend towards an increase in the registration of adverse events associated with the use of omalizumab.\",\"PeriodicalId\":406478,\"journal\":{\"name\":\"Glavvrač (Chief Medical Officer)\",\"volume\":\"87 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glavvrač (Chief Medical Officer)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33920/med-03-2208-07\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-03-2208-07","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Omalizumab is one of the longest-used monoclonal antibodies and the first available treatment option for severe allergic asthma in patients aged 6 years and older. Its efficacy and safety were established in several randomized controlled trials, leading to its final registration over 15 years ago. In most cases, long-term treatment with omalizumab is safe and does not increase the risk of adverse reactions. However, over the years, there has been a trend towards an increase in the registration of adverse events associated with the use of omalizumab.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
